香港联交所最新数据显示，11月14日，GL Capital Management GP Limited 增持归创通桥（02190）440万股，每股平均价24港元，总金额为1.056亿港元。增持后，GL Capital Management GP Limited 最新持股数目为2050万股，持股比例为6.09%。
公开资料显示，目前归创通桥股东包含奥博资本（Orbimed）、清池资本（Lake Bleu）、AIHC Capital等深耕中国医疗健康领域的专业投资机构。此次，德福资本（GL Capital）举牌归创通桥，再次体现了市场人士对归创通桥经营稳健性与成长潜力的信心。
近年来，归创通桥持续推进创新产品管线布局，加速核心产品在国内外市场的覆盖，并稳步拓展全球化运营能力。公司表示，未来将继续秉持“为生命恒创新”的理念，持续加大在医疗科技领域的研发与投入，为全球患者提供高质量且可负担的医疗器械产品与解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.